These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 28029415)

  • 61. Disagreement on cancer drug decisions in Europe.
    Maynou L; Cairns J
    Int J Technol Assess Health Care; 2020 Jun; 36(3):232-238. PubMed ID: 32538341
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Reimbursement Legislations and Decision Making for Orphan Drugs in Central and Eastern European Countries.
    Malinowski KP; Kawalec P; Trąbka W; Czech M; Petrova G; Manova M; Savova A; Draganić P; Vostalová L; Slabý J; Männik A; Márky K; Rugaja Z; Gulbinovic J; Tesar T; Paveliu MS
    Front Pharmacol; 2019; 10():487. PubMed ID: 31139080
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Reimbursement decisions in health policy--extending our understanding of the elements of decision-making.
    Wirtz V; Cribb A; Barber N
    Health Policy; 2005 Sep; 73(3):330-8. PubMed ID: 16039351
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Quality of health care, accreditation, and health technology assessment in Croatia: role of agency for quality and accreditation in health].
    Mittermayer R; Huić M; Mestrović J
    Acta Med Croatica; 2010 Dec; 64(5):425-34. PubMed ID: 21692267
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Sensitivity analysis in economic evaluation: an audit of NICE current practice and a review of its use and value in decision-making.
    Andronis L; Barton P; Bryan S
    Health Technol Assess; 2009 Jun; 13(29):iii, ix-xi, 1-61. PubMed ID: 19500484
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Assessing the impact of health technology assessment on the Austrian healthcare system.
    Schumacher I; Zechmeister I
    Int J Technol Assess Health Care; 2013 Jan; 29(1):84-91. PubMed ID: 23228411
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Prevention of overweight and obesity undertaken by local government units in Poland.
    Augustynowicz A; Czerw A; Borowska M; Deptała A; Dykowska G; Fronczak A
    Health Policy; 2019 May; 123(5):499-502. PubMed ID: 30926135
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Reimbursement of targeted cancer therapies within 3 different European health care systems.
    Mihajlović J; Dolk C; Tolley K; Simoens S; Postma MJ
    Clin Ther; 2015 Feb; 37(2):474-80. PubMed ID: 25638534
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Why do health technology assessment drug reimbursement recommendations differ between countries? A parallel convergent mixed methods study.
    Nicod E; Maynou L; Visintin E; Cairns J
    Health Econ Policy Law; 2020 Jul; 15(3):386-402. PubMed ID: 31488229
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The persistence of cliques in the post-communist state. The case of deniability in drug reimbursement policy in Poland.
    Ozierański P; King L
    Br J Sociol; 2016 Jun; 67(2):216-41. PubMed ID: 27206533
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Use of health technology assessment in drug reimbursement decisions in China.
    Chen W; Zhang L; Hu M; Hu S
    BMJ; 2023 Jun; 381():e068915. PubMed ID: 37321619
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Harmonization of evidence requirements for health technology assessment in reimbursement decision making.
    Hutton J; Trueman P; Facey K
    Int J Technol Assess Health Care; 2008; 24(4):511-7. PubMed ID: 18828948
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review.
    Chilcott J; Tappenden P; Rawdin A; Johnson M; Kaltenthaler E; Paisley S; Papaioannou D; Shippam A
    Health Technol Assess; 2010 May; 14(25):iii-iv, ix-xii, 1-107. PubMed ID: 20501062
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Objectivity of reimbursement decisions - does it always has to pay off?
    Kolasa K
    Przegl Epidemiol; 2013; 67(3):503-7, 599-603. PubMed ID: 24340569
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Changes of drug reimbursement expenses incurred by National Health Fund in Silesian voivodeship in the period of 1999-2004].
    Swistak P; Dzielicki M; Janiec R; Błońska-Fajfrowska B
    Wiad Lek; 2005; 58(9-10):495-9. PubMed ID: 16529058
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A synthesis of drug reimbursement decision-making processes in organisation for economic co-operation and development countries.
    Barnieh L; Manns B; Harris A; Blom M; Donaldson C; Klarenbach S; Husereau D; Lorenzetti D; Clement F
    Value Health; 2014; 17(1):98-108. PubMed ID: 24438723
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Risk sharing schemes--what does foreign experience tell us?].
    Kolasa K
    Pol Merkur Lekarski; 2013 Oct; 35(208):214-6. PubMed ID: 24340892
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The Fourth Hurdle: Commentary on "Weighing Of Evidence By Health Technology Assessment Bodies: Retrospective Study Of Reimbursement Recommendations For Conditionally Approved Drugs" by Vreman et al.
    Honig PK
    Clin Pharmacol Ther; 2019 Mar; 105(3):561-562. PubMed ID: 30346642
    [No Abstract]   [Full Text] [Related]  

  • 79. Weighing of Evidence by Health Technology Assessment Bodies: Retrospective Study of Reimbursement Recommendations for Conditionally Approved Drugs.
    Vreman RA; Bouvy JC; Bloem LT; Hövels AM; Mantel-Teeuwisse AK; Leufkens HGM; Goettsch WG
    Clin Pharmacol Ther; 2019 Mar; 105(3):684-691. PubMed ID: 30300938
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Implementation of the 2011 Reimbursement Act in Poland: Desired and undesired effects of the changes in reimbursement policy.
    Kawalec P; Sagan A; Stawowczyk E; Kowalska-Bobko I; Mokrzycka A
    Health Policy; 2016 Apr; 120(4):356-61. PubMed ID: 26994865
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.